阅读说明：本技术 右旋龙脑作为阿霉素钝化剂的应用 (Application of d-borneol as adriamycin passivator ) 是由 陈填烽 赖浩强 于 2018-10-17 设计创作，主要内容包括：本发明公开了右旋龙脑作为阿霉素钝化剂的应用。本发明是基于本发明发明人发现右旋龙脑在与阿霉素联合应用于肝癌细胞和黑色素瘤细胞中具有钝化阿霉素药效的作用,所提出的发明创造。右旋龙脑作为阿霉素钝化剂的应用,是将右旋龙脑作为阿霉素钝化剂在肿瘤机理研究中进行应用；或是将右旋龙脑制备成用于暂缓化疗并消除肿瘤患者体内阿霉素药效的阿霉素钝化剂。(The invention discloses application of d-borneol as an adriamycin passivator. The invention is based on the discovery that the dextro-borneol has the effect of inactivating the drug effect of the adriamycin when being combined with the adriamycin and applied to liver cancer cells and melanoma cells, and the invention is provided. The application of the d-borneol as the adriamycin passivator is to apply the d-borneol as the adriamycin passivator in the research of tumor mechanism; or the dextroborneol is prepared into adriamycin passivator for suspending chemotherapy and eliminating the effect of the adriamycin in the body of a tumor patient.)

1. Application of d-borneol as doxorubicin deactivator is provided.

2. Use of d-borneol as a deactivant for doxorubicin according to claim 1, characterized in that: d-borneol is used as an adriamycin passivator to be applied to the research of tumor mechanism; or the dextroborneol is prepared into adriamycin passivator for suspending chemotherapy and eliminating the effect of the adriamycin in the body of a tumor patient.

3. Use of d-borneol as a doxorubicin deactivator according to claim 1 or 2, characterized in that: the d-borneol is natural d-borneol.

4. Use of d-borneol as a deactivant for doxorubicin according to claim 2, characterized in that: the tumor is liver cancer or melanoma.

5. Use of d-borneol as a deactivant for doxorubicin according to claim 2, characterized in that: the adriamycin passivator comprises d-borneol and a pharmaceutically acceptable carrier.

6. Use of d-borneol as a deactivant for doxorubicin according to claim 5, characterized in that: the adriamycin passivator also comprises other components which are effective in passivating the pharmaceutical effect of the adriamycin.

7. Use of d-borneol as a deactivant for doxorubicin according to claim 5, characterized in that: when the tumor is melanoma, the dosage of the adriamycin passivator is calculated according to the ratio of 40-160 mu g of dextroborneol to 0.03125-1 nmol of adriamycin.

8. Use of d-borneol as a deactivant for doxorubicin according to claim 7, characterized in that: the dosage of the adriamycin passivator is calculated according to the ratio of 0.451-0.546 nmol to 40-160 mug of dextroborneol and adriamycin.

9. Use of d-borneol as a deactivant for doxorubicin according to claim 5, characterized in that: when the tumor is liver cancer, the dosage of the adriamycin passivator is calculated according to the ratio of 40-80 mu g of dextroborneol to 0.561-0.662 nmol of adriamycin.

Technical Field

The invention relates to application of d-borneol, in particular to application of d-borneol as an adriamycin passivator.

Background

Doxorubicin (Doxorubicin, DOX) belongs to the anthracycline antimetabolites and is one of the most clinically effective and widely used antineoplastic drugs. Doxorubicin can intercalate directly into the DNA molecule in an additive fashion between base pairs, causing DNA damage. The chimeric DOX can cause the synthesis of DNA and RNA to be blocked, can inhibit the activity of topoisomerase and destroy the high-level structure of DNA, and is widely used for treating breast cancer, bladder cancer, lung cancer, ovarian cancer and the like. However, doxorubicin has obvious toxic and side effects, 11% of patients have acute toxicity after treatment, and the doxorubicin belongs to one of chemotherapy drugs which are easy to cause liver damage, primary and acquired resistance of the doxorubicin also greatly influences the effect of chemotherapy, and the patients are difficult to tolerate or continue to finish treatment due to the toxic and side effects of high-dose chemotherapy drugs. Therefore, in patients who are difficult to tolerate the adverse effects of chemotherapy, it is necessary to suspend the chemotherapy and eliminate the effect of doxorubicin in the patient.

Borneol (borneel), commonly known as borneol, is a terpene and bicyclic organic compound extracted from resin and volatile oil of Dipterocarpaceae plant, and belongs to monoterpene alcohol, and is used for treating block pattern of coma, conjunctival congestion, sore throat, aphtha, sore and ulcer, unhealing after ulceration, coronary heart disease and angina pectoris. The d-borneol has low toxicity to normal cells of a human body and basically has no obvious influence. At present, the D-borneol is found to promote the medicine to pass through a blood brain barrier, and has sensitization effect on curcumin and derivatives thereof in melanoma cells, liver cancer cells and breast cancer cells. No report that D-borneol is used as an antitumor drug passivator exists, and the application of D-borneol as the passivator for weakening the drug effect of DOX and the drug resistance and toxic and side effects of chemotherapy has important research significance.

Disclosure of Invention

The invention aims to overcome the defects in the prior art and provide the application of the d-borneol as the adriamycin passivator.

The purpose of the invention is realized by the following technical scheme: the application of the d-borneol as the adriamycin passivator is based on the discovery that the d-borneol has the effect of passivating the drug effect of the adriamycin when being combined with the adriamycin to be applied to liver cancer cells and melanoma cells.

The application of the d-borneol as the adriamycin passivator is to apply the d-borneol as the adriamycin passivator in the research of tumor mechanism; or the dextroborneol is prepared into adriamycin passivator for suspending chemotherapy and eliminating the effect of the adriamycin in the body of a tumor patient.

The d-borneol is natural d-borneol.

The tumor is liver cancer or melanoma.

The adriamycin passivator comprises d-borneol and a pharmaceutically acceptable carrier.

The adriamycin passivator also comprises other components which are effective in passivating the pharmaceutical effect of the adriamycin.

When the tumor is melanoma, the dosage of the adriamycin passivator is calculated according to the ratio of 40-160 mug of dextroborneol to 0.03125-1 nmol of adriamycin; more preferably, the amount of D-borneol and adriamycin is 40-160 mug: 0.451-0.546 nmol.

When the tumor is liver cancer, the dosage of the adriamycin passivator is calculated according to the ratio of 40-80 mu g of dextroborneol to 0.561-0.662 nmol of adriamycin.

Compared with the prior art, the invention has the following advantages and effects:

the invention discovers that the effect of the adriamycin on melanoma cells and liver cancer cells can be reduced by using the dextroborneol as an adriamycin passivator, and the effect is completely different from that of the dextroborneol reported in the prior art. The d-borneol has different effects when combined with different antitumor drugs for use in different tumor cells, which opens up a way for researching different tumor mechanisms. Based on the strong side effect of the adriamycin, the d-borneol can reduce the drug effect of the adriamycin on melanoma cells and liver cancer cells, and can be used for suspending chemotherapy, eliminating the drug effect of the adriamycin in a patient body, reducing toxic and side effects and weakening chemotherapy resistance.

DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION

The present invention will be described in further detail with reference to specific examples, but the embodiments of the present invention are not limited thereto.